SCHEMBL6824997

SCHEMBL6824997

COc1cccc2c1CCC(Cc1ccncc1)=C2C

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 9/20 0.53
LMNA P02545 2/20 0.41
CYP17A1 P05093 2/20 0.41
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822335 0.86 CYP19A1 (0.50) CYP19A1LMNACYP17A1MAPTSMN1; SMN2
SCHEMBL6825267 0.86 P2RX7 (0.45) CYP19A1CYP17A1KDM4EALDH1A1
SCHEMBL7457634 0.84 CYP19A1 (0.48) CYP19A1LMNAMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL7453886 0.83 CYP19A1 (0.47) CYP19A1LMNAMAPTSMN1; SMN2
SCHEMBL6825301 0.81 CYP19A1 (0.49) CYP19A1CYP17A1
SCHEMBL6825523 0.77 CYP19A1 (0.38) CYP19A1CYP17A1
SCHEMBL6827592 0.77 CHRM2 (0.47) CYP19A1CYP17A1
SCHEMBL6825674 0.74 CYP19A1 (0.47) CYP19A1LMNACYP17A1MAPTSMN1; SMN2
SCHEMBL6825612 0.73 CYP19A1 (0.53) CYP19A1LMNACYP17A1MAPTSMN1; SMN2
SCHEMBL6827784 0.73 CYP19A1 (0.65) CYP19A1LMNACYP17A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028110-B1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME DAIICHI SEIYAKU CO (JP) 2004-04-14 EP disclosed
US-6559157-B2 Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-05-06 US disclosed
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same DAIICHI PHARMACEUTICALS CO., LTD. (JP) 2002-03-14 US disclosed
EP-1028110-A1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME Yukijirushi Nyugyo Kabushiki Kaisha (JP) 2000-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same CYP19A1, HSD17B11, CYP17A1 CYP19A1 1/4885LMNA 1404/4885CYP17A1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.